Skip to main content
232 search results for:

Sodium-glucose cotransporter-2 inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-16-2018 | Type 1 diabetes | Editorial | Article

    Sodium-glucose cotransporter-2 inhibitors for type 1 diabetes: Ready for prime time?

    Editorial board member John Wilding casts a critical eye over the positive buzz surrounding the potential uses of sodium-glucose cotransporter 2 inhibitors in type 1 diabetes treatment.

  2. 10-01-2016 | SGLT2 inhibitors | Review | Article

    Sodium-glucose cotransporter-2 inhibitors: benefit/risk balance

    Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycemia by increasing urinary glucose excretion.

  3. 03-28-2018 | Cardiovascular disorders | Article

    Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death, and safety outcomes in type 2 diabetes: A systematic review

    Rådholm K et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.03.027

  4. 05-04-2018 | SGLT2 inhibitors | Review | Article

    Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

    A systematic review and meta-analysis

    The authors compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using

  5. 03-25-2018 | SGLT2 inhibitors | Article

    Sodiumglucose co‐transporter‐2 inhibitors as add‐on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials

    Yamada T et al.  Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13260

  6. 04-09-2018 | SGLT2 inhibitors | Article

    Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis

    Zhang L et al. Diabetes Res Clin Prac 2018; Advance online publication. doi: 10.1016/j.diabres.2018.03.047

  7. 06-07-2016 | SGLT2 inhibitors | Review | Article

    Sodium-glucose cotransporter-2 inhibitors in the management of type 2 diabetes

    The glucose-lowering pharmacopeia continues to grow for patients with type 2 diabetes.

  8. 09-30-2016 | SGLT2 inhibitors | Article

    Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

    Diabesity—obesity resulting in diabetes—is a major health problem globally because of the obesity epidemic.

  9. 12-01-2014 | SGLT2 inhibitors | Review | Article

    Sodium glucose cotransporter-2 inhibitors: A review of their basic and clinical pharmacology

    Kalra S.  Diabetes Ther 2014; 5: 355–366. doi: 10.1007/s13300-014-0089-4

  10. 08-31-2023 | Type 2 diabetes | News | Article

    Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

    SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

  11. 09-04-2023 | Type 2 diabetes | News | Article

    New model predicts kidney disease progression risk in type 2 diabetes

    Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

  12. 12-05-2022 | SGLT2 inhibitors | News | Article

    Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

    An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

  13. 01-12-2023 | Older adults | News | Article

    Lower glucose may slow ageing in type 2 diabetes

    People with type 2 diabetes who maintain low glycated haemoglobin levels have slower progression of frailty over time than those with higher levels, shows an analysis of Look AHEAD participants.

  14. 10-24-2022 | Cardiovascular outcomes | News | Article

    Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection

    Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine .

  15. 11-01-2022 | SGLT2 inhibitors | News | Article

    Real-world adjunctive medication outcomes in type 1 diabetes revealed

    People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

  16. 10-04-2022 | Healthcare costs | News | Article

    First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

    The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

  17. 11-18-2022 | Dapagliflozin | News | Article

    Dapagliflozin HFpEF benefits independent of glucose levels

    People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

  18. 02-08-2023 | Heart failure | News | Article

    Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

    A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

  19. 08-25-2022 | Physical activity | News | Article

    Initiating glucose-lowering therapy may be linked to a reduction in physical activity

    Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.

  20. 11-08-2022 | SGLT2 inhibitors | News | Article

    Meta-analysis backs SGLT2 inhibitors for kidney disease

    A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.